Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018

Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018

  • October 2018 •
  • 59 pages •
  • Report ID: 5028285
“Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” by DelveInsight offers comprehensive Insight on marketed and Phase III products for Fabry Disease. The marketed products information covers their product details, patents (US & EU)*, historical and forecasted sales till 2022. It further provides the marketed products’ API manufacturer details for United States, Europe, China, and India.* The report also covers the emerging Phase III pipeline assets for Infantile Spasm including their detailed product profiles. Additionally, the report also highlights the future competitive landscape for Fabry Disease therapeutics.
*Depending on information availability
Comprehensive coverage of the following for Fabry Disease:
Marketed Products for Fabry Disease
Descriptive marketed product profiles for Fabry Disease including (but not limited to) drug description, regulatory milestones, product development and R&D activities encompassing clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are the historical and forecasted global sales till 2022 for each product.

Global API Manufacturers of Marketed Products for Fabry Disease
Coverage of API manufacturers for Fabry Disease marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location

Emerging Phase III products for Fabry Disease
Descriptive Phae III product profiles for Infantile Spasm including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are their forecasted global sales till 2022.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.


Scope of the report
• A comprehensive coverage of Fabry Disease marketed products including product description, regulatory milestones, clinical trials, deals and partnerships have been elaborated in this report
• Patent information around Fabry Disease marketed products in United States (US) and Europe (EU) has been highlighted
• API manufacturers details for Fabry Disease marketed therapeutics in United States, Europe, China and India
• Comprehensive coverage of the emerging therapies (Phase III) for Fabry Disease including their product description, research and development activities, collaborations and licensing deals, drug mechanism and chemical information
• The report contains historical and forecasted global sales till 2022 for each marketed product and forecasted sales till 2022 for emerging Phase III products for Fabry Disease

Reasons to Buy
• Establish a comprehensive understanding of Fabry Disease marketed and emerging (Phase III) products
• Access to API manufacturers details for Fabry Disease marketed drugs to devise API procurement strategy for generic development
• Plan developmental timelines around marketed drug patents for the major markets- US and EU
• Understand current and future growth of marketed Fabry Disease therapeutics through their historical and forecasted sales
• Identify and analyze future sales trends of emerging Phase III Fabry Disease therapeutics through their forecasted sales
• Identify the products attributes and use it for target finding, drug repurposing, and precision medicine
• Identify and plan ahead for prospective emerging players and their products for Fabry Disease
Country=UnitedStates Industry=MentalHealth ParentIndustry=LifeSciences Date=201810 Topic=Demand Publisher=DelveInsight Price=2000